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Objectives: To examine the association between gout severity and (i) socioeconomic status; (ii) work 
absence. 
Methods: Postal questionnaires were sent to adults registered with 20 general practices who had 
consulted with gout or been prescribed allopurinol or colchicine in the preceding two years. Gout severity 
was defined using proxy measures: number of attacks, history of oligo/polyarticular attacks, disease 
duration, and allopurinol use. Socioeconomic status (SES) was defined using the English index of multiple 
deprivation (IMD) (area-level) using self-reported educational attainment (individual level). Work absence 
was defined as taking time off work in the past 6 months because of gout. Adjusted odds ratios (aOR, 95% 
confidence intervals) were calculated using logistic regression models (adjusted for age, gender, BMI, gout 
severity, co-morbidities). 
Results: 1184 completed questionnaires were returned. Mean age was 65.6 years, 84% male. Not having 
attended further education was associated with having had ≥2 gout attacks in the last year (aOR 0.54; 
0.36, 0.81) and oligo/polyarticular attacks (0.72; 0.50, 1.05). Lower area-level deprivation was associated 
with fewer attacks (aOR ≥2 attacks 0.71; 0.51, 0.98). Work absence was associated with having ≥2 attacks 
in the last year (2.91; 1.22, 6.92), oligo/polyarticular attacks (3.10; 1.46, 6.61) and shorter disease 
duration (>18 years: 0.13; 0.03, 0.50). 
Conclusion: Gout severity was associated with individual level deprivation, countering the historical and 
unhelpful perception of gout as a “rich man’s disease”. The association of gout severity with work absence 




Significance and Innovations 
 Frequency of gout attacks was associated with both individual and area-level deprivation 
 Two or more gout attacks in the last year was associated with a marked increase in work 
absence, suggesting a need for tighter control in primary care 
 Disease duration was inversely correlated with work absence, suggesting patients may develop a 




Gout is the most common inflammatory joint disease affecting men aged over 40 in the UK with a national 
prevalence of 2.5% in the adult population (1), a prevalence similar in other developed countries such as 
the US and New Zealand (2, 3). Gout is caused by hyperuricaemia, which reaches a threshold where 
monosodium urate (MSU) crystals form and are deposited in joints, most commonly within the 1
st
 
metatarsophalangeal joint (MTP) (4). In the UK, most people with gout are managed entirely in primary 
care. 
 
It is important to understand the socioeconomic status (SES) of a community affected by a condition to 
ensure that care is distributed according to need. There are many studies of social deprivation and health 
outcomes, which show that being from a lower SES group is associated with increased GP attendance and 
poorer health (5, 6). Some of these studies (e.g. (6)), have been conducted at neighbourhood and 
individual levels, to try and tease out whether any association is due to community factors or factors 
pertaining more specifically to the patients. The few studies investigating the association between gout 
and SES provide contrasting results. In the UK, a recent study found that perceiving financial income to be 
inadequate was more common in people with gout aged 50 years and over compared with those without 
gout. However, no association was seen between the presence of gout and occupational class, 
educational attainment or area-level deprivation (7).  Similarly, no association with area-level deprivation 
was found in Australia (8,9). A study from Western Germany reported an association between gout and 
SES in women but not men (10). Studies from England and New Zealand have shown that the prevalence 
of gout is highest in more socioeconomically deprived areas (4, 11). These existing studies have largely 
compared SES between people with and without gout. There are very few existing studies of the 
relationship between gout severity and SES. One study from Mexico did not find a relationship between 
the presence of tophi and either socioeconomic status or education level (12).  
 
Due to the severity of acute gout, people are often unable to work, leading to short-term sick leave (13). 
The effect of gout on work ability, productivity, and employability has been shown to be a major concern 
of people with gout (14). Employees with gout have nearly five times more annual health-related absence 
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days than those without gout (15). The total annual employers’ health benefit costs of an employee with 
gout in the USA has been shown to be almost twice that of an employee without gout ($6870 versus 
$3705) (16). Employees with gout who experience at least three gout attacks per year have more days of 
work absence than those having less frequent attacks (17). In a study of patients with severe chronic gout, 
refractory to conventional therapy (mean number of attacks 8.8 per year), 78% of those aged under 65 
years of age reported being absent from work due to gout for at least 1 day in a one-year period and the 
mean annual number of work-days lost was 25 days (18). Work productivity has been shown to be 
impaired in those with inadequately-controlled gout despite urate-lowering therapy compared to those 
whose control was adequate (19). In contrast, one small study found no association between number of 
attacks or tophi and work productivity (20). 
 
The aim of this study was to investigate the association between gout severity and 1) SES at the 
individual- and area-levels; and 2) work absence. 
 
Patients and Methods 
Study Population 
The study used cross-sectional baseline data from a three-year primary care-based prospective 
observational study across 20 GP practices in the West Midlands, UK (21). Medical records were searched 
to identify patients older than 18 years who had a Read-coded consultation for gout or a prescription for 
allopurinol or colchicine in the preceding two years. Ethical approval was received from the North West – 
Liverpool East Research Ethics Committee (12/NW/0297). 
 
Data collection 
Potential participants were mailed by post a study pack, invitation to take part and a baseline survey 
questionnaire. Non-responders were mailed reminders two and four weeks after initial contact. 
Responders were asked to provide consent to review of their medical records. 
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Gout Severity measures 
Gout severity was determined using proxy measures from the baseline questionnaire. As recommended 
by OMERACT (22), measures of gout severity included number of acute attacks experienced in the past 
year (categorised as no attacks, one attack or more than one attack) and presence of tophi (determined 
from primary care medical records in consenting participants). A history of oligo/polyarticular attacks 
(ever having an attack of gout affecting more than one joint at the same time), current use of allopurinol, 
and gout duration (participant’s current age minus self-reported age at diagnosis, categorised into 
quartiles) were also included. These were considered to have face-validity as indicators of gout severity as 
the number of joints involved in attacks associates with poorer health-related quality of life (23), 
allopurinol prescription is more likely in people having frequent attacks or tophi (24), and people with 
longer disease duration have more frequent attacks (25-27). 
 
Socioeconomic measures 
Area-level deprivation was assessed using the English Indices of Multiple Deprivation (IMD) 2010 (28). The 
IMD divides the country into 32,482 lower-layer super-output areas (LSOAs) each with approximately 
1500 people. These are assessed for deprivation across several domains (weighting): income deprivation 
(22.5%); employment deprivation (22.5%); health deprivation and disability (13.5%); education, training 
and skills deprivation (13.3%); barriers to housing and services (9.3%); crime (9.3%); and living 
environment deprivation (9.3%). IMD scores are then ranked, with 1 being the most deprived. For the 
purpose of this study, the rankings were divided into three tertiles: least deprived, mid-deprived and most 
deprived. In order to assess individual-level deprivation, participants were asked if they had gone on from 
school into full-time education or university (yes/no).  
 
Work absence 
Current employment was defined as either having a full-time or part-time job, or being employed but 
currently being off sick for six months or less (21). Participants were asked if they had taken time off work 




Age, gender, body mass index (BMI) (calculated from self-reported height and weight) and history of co-
morbidities (diabetes, hypertension, stroke, transient ischaemic attack (TIA), hyperlipidaemia, kidney 
failure, kidney stones, angina and myocardial infarction) were obtained from questionnaire responses. 
 
Analysis 
Descriptive statistics were used to characterise the sample. Multilevel mixed-effects binary logistic 
regression models were used to assess the association between gout severity (attack frequency, history of 
oligo/polyarticular attacks, gout duration, current allopurinol use, tophi) and (i) further education and (ii) 
having had time off work because of gout. Multilevel mixed-effects ordinal logistic regression models 
were used to assess the association between gout severity and tertile of deprivation. The assumption of 
proportional odds in these models was assessed using a likelihood ratio test and a partial proportional 
odds model fitted as required. In all models, a random effect was estimated for general practice. Results 
are presented as unadjusted odds ratios (OR) with 95% confidence intervals (CI) and then adjusted for 
age, gender, BMI, other gout severity variables and co-morbidities. Analyses were conducted using SPSS 




In total, 1184 people responded to the survey (adjusted response 66%), 1079 of whom provided consent 
for their medical records to be reviewed. As reported previously, responders tended to be older and were 
more likely to be male and live in less deprived areas than non-responders (31). Mean age was 65.6 (SD 
12.5) years. The majority (83.6%) were male, Caucasian (97.6%) and had not attended further education 
(77.8%) (Table 1). Eight hundred and ninety-eight people (83.3%) were overweight or obese. Mean gout 
duration was 11.9 (SD 12.1) years, with 494 (44.0%) experiencing two or more attacks in the last year. 
Previous oligo/polyarticular attacks were reported by 436 (38.6%). Over half were currently using 
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allopurinol (630 (56.3%)) and 345 (32%) had a prescription for colchicine in the previous two years. Tophi 
were recorded in the medical record in the preceding two years for only 25 (2.4%). Of 394 who were 
currently employed, 75 (19.0%) reported having taken time off work in the last 6 months as a result of 
gout.  
 
Socioeconomic deprivation  
Attendance at further education was associated with approximately half the odds of having had two or 
more attacks in the last year (Table 2), an association which remained following adjustment for potential 
confounders (aOR 0.54 (95%CI 0.36, 0.81)). Those who attended further education also less frequently 
reported having had oligo/polyarticular attacks although this was not statistically significant (aOR = 0.72 
(0.50, 1.05)). There were no significant associations between attendance at further education and disease 
duration, current allopurinol use or the presence of tophi (Table 2). 
Greater area level deprivation (IMD) was associated with having two or more gout attacks in the last year 
(Table 3). This association remained after adjustment (aOR 0.71 (0.51, 0.98)). There were no significant 
associations between area-level deprivation and disease duration, history of oligo/polyarticular attacks, 




Amongst those in current employment (n=394), taking time off work in the last six months because of 
gout was significantly more likely in those who had had two or more attacks compared to a single attack 
in the last year (aOR = 2.91 (95%CI 1.22, 6.92)) (Table 4). Similarly, those who had a history of 
oligo/polyarticular attacks had over three times the odds of taking time off work (3.10 (1.46, 6.61)). In 
contrast, people who had longer gout duration were less likely to take time off work. No significant 
association found between time off work and current allopurinol use. The association between tophi and 
work absence was not examined because there were insufficient participants in current employment who 




This study is the first to examine the association of gout severity with SES, providing unique data for 
clinicians and policy makers. Attendance at further education and area-level deprivation were associated 
with a lower frequency of attacks. Work absence because of gout was more common in those with 
frequent attacks and a history of oligo/polyarticular attacks but less common in those with longer 
duration of gout.  
 
To our knowledge, only one previous study has examined the association between gout severity and SES, 
finding no statistically significant differences between those with severe and non-severe tophaceous gout 
(12). We found that non-attendance at further education was associated with more frequent attacks, a 
previous primary-care based study found that this did not differ between people with or without gout (7). 
This suggests that although the presence or absence of gout may not be influenced by educational 
attainment, level of education may be a risk factor for more severe gout. Although our data are cross-
sectional, attending further education most commonly occurs early in life prior to the typical age of gout 
onset. In contrast, we found no association between educational attainment and oligo/polyarticular 
attacks, allopurinol usage, gout duration or tophi. Tophi are an infrequent finding in primary care gout 
populations and hence this finding may represent a type II error. The lack of association between 
allopurinol use and either measure of SES suggests that allopurinol prescription is not influenced by 
deprivation, although it remains possible that suboptimal titration of allopurinol is more common with 
greater deprivation, which might be suggested by the greater attack frequency in those not attending 
further education. We were unable to explore this possibility in this dataset. Our finding that the 
frequency of gout attacks was associated with greater area-level deprivation is consistent with studies 




We found that work absence was more common amongst those with more frequent attacks or a history 
of oligo/polyarticular attacks. Previous studies have reported more work absence days in those with more 
frequent attacks (17, 18), presumably reflecting the severe pain and difficulty weight bearing associated 
with acute gout. These studies have not examined the association of work absence with a history 
oligo/polyarticular attacks.  The finding that, amongst those in current employment, work absence was 
less likely in those with longer gout duration was unexpected. Our study cannot elucidate the reasons for 
this. However, it is plausible that people with longer duration of disease might be better able to reduce 
the impact of attacks (for example, by being better prepared to start treatment for attacks as soon as 
possible after onset) or could already have adjusted their working practices or changed their job to 
accommodate the unpredictability and debilitating nature of attacks.  
 
The strengths of this study are the sample size and the primary care setting, maximising the 
generalisability of the results to the majority of patients with gout who are managed exclusively in 
primary care. Our choice of gout severity markers has not been validated as such, however, attacks and 
tophi have been highlighted as essential domains for chronic gout studies by OMERACT, and both attacks 
and the number of joints involved associate with poorer health-related quality of life (22, 23). Despite the 
large sample size, only a very small number had tophi documented in their medical records. Whilst this 
reflects the milder spectrum of disease seen in primary care, we were unable to examine the effect of 
tophaceous disease as a result. Comorbidities were ascertained by participant-report rather than from 
medical records because not all participants provided consent to record review. Although this could 
potentially introduce bias, the validity of self-reporting comorbidities has been previously shown (32, 33). 
A further limitation is that we included only a single measure of individual-level socioeconomic 
deprivation (education) and neglected to collect information on income, occupation, number of days lost 
from work, previous (rather than current) allopurinol use, or other gout treatments. Importantly, the 
diagnosis of gout in this study was based on a general practitioner’s diagnosis of gout rather than crystal 
identification or gout classification criteria, risking misclassification bias. However, primary care coding of 
gout by general practitioners has been shown to have a high positive predictive value (34). Similarly, we 
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did not consider the value of SUA as a marker of gout severity or control, as this was only recorded in the 
medical records of 461 people (39% of the cohort).  
 
Our finding that poor socioeconomic status was associated with more frequent attacks is contrary to the 
historical perception of gout as a rich man’s disease (35). This is important as this stereotype, along with 
associated perceptions about gout being caused by dietary excess, may contribute to delayed 
consultation and reluctance to acknowledge having gout, particularly by women (36). Further research is 
needed to explore temporal aspects of the associations between gout severity and socioeconomic 
deprivation and work absence in longitudinal studies. The observation that work absence was less 
common in people with longer gout duration is worthy of further study as it may provide insights into 
how patients with gout manage both the disease and their work life in order to optimise their fitness to 
work. Our finding that both greater attack frequency and having oligo/polyarticular attacks was 
associated with work absence reinforces the case for treating people with urate-lowering therapy earlier 
in the course of the disease and suggests that work is an important outcome for future trials of 
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Table 1: Participant characteristics (n = 1184) 
Variable 
 n= 1184 
(%) 
Gender (n (%))   
 Male 990 (83.6) 
 Female 194 (16.4) 
Age, years (Mean (SD)) 65.6 (12.5) 
Ethnicity (n (%))   
 White 1126 (97.6) 
 Non-white 28 (2.4) 
BMI, Kg/m
2 
(n (%))   
 <25 221 (19.8) 
 25-29.9 511 (45.7) 
 30-34.9 260 (23.2) 
 ≥35 127 (11.4) 
Frequency of alcohol consumption  
 Daily 273 (23.4) 
 3-4 times a week 263 (22.5) 
 1-2 a week 254 (21.8) 
 1-3 times a month 109 (9.3) 
 Special occasions 155 (13.3) 
 Never 113 (9.7) 
Anxiety, GAD (n (%))   
 None 844 (77.2) 
 Mild 141 (12.9) 
 Moderate 64 (5.9) 
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 Severe 45 (4.1) 
Depression, PHQ (n (%))   
 None 763 (73.2) 
 Mild 148 (14.2) 
 Moderate 65 (6.2) 
 Moderately severe 40 (3.8) 
 Severe 26 (2.5) 
Gout Characteristics   
Disease duration, years (mean, (SD)) 11.9 (12.1) 
Number of attacks in last 12 months   
 0 398 (35.4) 
 1 231 (20.6) 
 ≥2 494 (44.0) 
Oligo/Polyarticular attacks 436 (38.6) 
Current allopurinol use 630 (56.3) 
Tophi 25 (2.4) 
Socioeconomic indicators   
Attended higher education   
 Yes 249 (22.3) 
Neighbourhood deprivation, IMD (N (%))   
 Most deprived 369 (31.2) 
 Mid-deprived 405 (34.21) 
 Least deprived 410 (34.6) 
Work Disability   
Have you taken time off work during last 6 months because of gout? (n (%)) 75 (19.1) 
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Table 2: Association between gout severity and attendance at higher education  
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Odds ratio (95% confidence 
interval) 
Number of attacks in last 12 
months 
    Unadjusted Adjusted
a
 
 0 105 (43.2) 275 (33.4) 1 1 
 1 58 (23.9) 161 (19.5) 0.94 (0.65, 1.37) 0.93 (0.59, 1.46) 
 ≥ 2 80 (32.9) 388 (47.1) 0.54 (0.39, 0.75) 0.54 (0.36, 0.81) 
Disease duration (years)         
 <2 62 (25.7) 222 (27.7)  1 1 
 3-8 58 (24.1) 207 (25.8) 1.01 (0.67, 1.51) 1.06 (0.66, 1.72) 
 8-18 63 (26.1) 183 (22.8) 1.24 (0.83, 1.86) 1.36 (0.82, 2.23) 
 ≥19 58 (24.1) 190 (23.7) 1.09 (0.73, 1.65) 1.20 (0.70, 2.03) 
Oligo/polyarticular attacks         
 No 165 (67.1) 499 (60.3) 1 1 
 Yes 81 (32.9) 329 (39.7) 0.75 (0.55, 1.01) 0.72 (0.50, 1.05) 
Current allopurinol use         
 No 105 (43.6) 355 (43.3) 1 1 
 Yes 136 (56.4) 465 (56.7) 0.98 (0.74, 1.32) 0.82 (0.55, 1.21) 
Tophi         
 No 228 (99.1) 765 (97.2) 1 1 
 Yes 2 (0.9) 22 (2.8) 0.31 (0.07, 1.31) 0.38 (0.08, 1.73) 
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a
adjusted for other variables in table, age, sex, BMI, comorbidities (diabetes, stroke, hypertension, TIA, 
hyperlipidaemia, kidney failure, heart attack, kidney stones, angina) and IMD tertile. 
  
 22 
Table 3: Association between gout severity and IMD rankings divided into tertiles  












OR (CI) of IMD  
Number of attacks in 
last 12 months 
      Unadjusted Adjusted
a
 
 0 92 (26.7) 154 (39.6) 152 (39.1)  1  1 
 1 66 (19.1) 79 (20.3) 86 (22.1) 0.85 (0.62, 1.16) 1.01 (0.69, 1.49) 
 ≥ 2 187 (54.2) 156 (40.1) 151 (38.8) 0.68 (0.52, 0.88) 0.71 (0.51, 0.98) 
Disease duration 
(years) 
          
 <2 93 (27.7) 112 (29.6) 97 (25.3) 1 1 
 2-8 92 (27.4) 84 (22.2) 97 25.3) 1.06 (0.77, 1.47) 1.04 (0.71, 1.52) 
 8-18 73 (21.7) 85 (22.4) 99 (25.9) 1.41 (1.01, 1.97) 1.26 (0.84, 1.89) 
 >18 78 (23.2) 98 (25.9) 90 (23.5) 1.05 (0.76, 1.45) 0.94 (0.62, 1.43) 
Oligo/polyarticular 
attacks 
          
 No 194 (26.1) 251 (63.7) 250 (63.9)  1 1 
 Yes 152 (43.9) 143 (36.3) 141 (36.1) 0.85 (0.67, 1.07) 1.11 (0.82, 1.48) 
Current allopurinol 
use 
          
 No 156 (45.4) 160 (41.2) 174 (44.9)  1 1 
 Yes 188 (54.7) 228 (58.8) 214 (55.2) 1.02 (0.81, 1.29) 1.03 (0.75, 1.40) 
Tophi           
 No 318 (97.9) 359 (97.3) 361 (97.8)  1 1 
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 Yes 7 (2.2) 10 (2.7) 8 (2.2) 0.94 (0.44, 2.01) 1.25 (0.53 ,2.97) 
a
adjusted for other variables in table, age, sex, BMI, comorbidities (diabetes, stroke, hypertension, TIA, 
hyperlipidaemia, kidney failure, heart attack, kidney stones, angina) and further education status 
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Table 4: Work disability as related to gout severity (n=394) 
  Have you taken time off work during last 6 months because of gout? 
Gout characteristics  Time off, n (%) No time off, n (%) OR (CI) of having taken time off work 
Number of attacks in 
last 12 months
b
     Unadjusted Adjusted
a
 
 1 9 (12.9) 63 (35.0) 1 1 
 ≥2 61 (87.1) 117 (65.0) 3.65 (1.70, 7.83) 2.91 (1.22, 6.92) 
Disease duration 
(years)         
 <2 30 (41.7) 81 (26.9) 1 1 
 2-8 21 (29.2) 79 (26.3) 0.72 (0.38, 1.38) 0.52 (0.22, 1.26) 
 8-18 16 (22.2) 71 (23.6) 0.62 (0.31, 1.25) 0.31 (0.11, 0.85) 
 >18 5 (6.9) 70 (23.3) 0.19 (0.07, 0.52) 0.13 (0.03, 0.50) 
Oligo/polyarticular 
attacks         
 No 32 (43.8) 191 (62.6) 1 1 
 Yes 41 (56.2) 114 (37.4) 2.21 (1.30, 3.74) 3.10 (1.46, 6.61) 
Current allopurinol 
use         
 No 36 (50.0) 132 (44.2) 1 1 
 Yes 36 (50.0) 167 (55.9) 0.79 (0.47, 1.32) 1.99 (0.94, 4.23) 
a
adjusted for number of attacks, disease duration quartiles, poly-oligoarticular attacks, current allopurinol 
use, age, sex, BMI and comorbidities (diabetes, stroke, hypertension, TIA, hyperlipidaemia, kidney failure, 
heart attack, kidney stones, angina) 
b
Analysis restricted to those reporting ≥1 attack in last 12 months (n=270)
  
 
